Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 6/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348519 | 1.00 | POLB (0.43) | POLBRENGAAELANECTSG | |
| SCHEMBL7350730 | 0.89 | KDM4E (0.45) | POLBGAAELANECTSGKDM4E | |
| SCHEMBL4455542 | 0.89 | KDM4E (0.45) | POLBGAAELANECTSGKDM4E | |
| SCHEMBL7348947 | 0.88 | CAPN1 (0.46) | POLBRENGAAKDM4EACE | |
| SCHEMBL7347210 | 0.86 | GAA (0.46) | POLBRENGAAKDM4EACE | |
| SCHEMBL7348400 | 0.86 | REN (0.44) | POLBRENGAAKDM4EACE | |
| SCHEMBL7375211 | 0.86 | REN (0.44) | POLBRENGAAKDM4EACE | |
| SCHEMBL7347374 | 0.84 | REN (0.44) | POLBRENGAAKDM4EACE | |
| SCHEMBL6701578 | 0.84 | REN (0.44) | POLBRENGAAKDM4EACE | |
| SCHEMBL7349620 | 0.82 | REN (0.44) | POLBRENGAAKDM4EACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993025574-A1 | INHIBITORS OF ANGIOTENSIN I CHYMASE(S) INCLUDING HUMAN HEART CHYMASE | PFIZER INC. (US) | 1993-12-23 | — | — | WO | disclosed |